Avelumab With Valproic Acid in Virus-associated Cancer (LATENT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03357757
Recruitment Status : Recruiting
First Posted : November 30, 2017
Last Update Posted : June 12, 2018
EMD Serono
Information provided by (Responsible Party):
AHS Cancer Control Alberta

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : October 31, 2021
  Estimated Study Completion Date : February 26, 2027